Verastem (VSTM) Stock Forecast, Price Target & Predictions
VSTM Stock Forecast
Verastem stock forecast is as follows: an average price target of $8.33 (represents a 196.44% upside from VSTM’s last price of $2.81) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
VSTM Price Target
The average price target for Verastem (VSTM) is $8.33 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $13.00 to $5.00. This represents a potential 196.44% upside from VSTM's last price of $2.81.
VSTM Analyst Ratings
According to 4 Wall Street analysts, Verastem's rating consensus is 'Buy'. The analyst rating breakdown for VSTM stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Verastem Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 29, 2024 | Graig Suvannavejh | Mizuho Securities | $7.00 | $2.77 | 152.71% | 149.11% |
| May 24, 2024 | Justin Zelin | BTIG | $13.00 | $4.12 | 215.53% | 362.63% |
| Apr 15, 2022 | Gregory Renza | RBC Capital | $5.00 | $1.77 | 182.49% | 77.94% |
The latest Verastem stock forecast, released on Jul 29, 2024 by Graig Suvannavejh from Mizuho Securities, set a price target of $7.00, which represents a 152.71% increase from the stock price at the time of the forecast ($2.77), and a 149.11% increase from VSTM last price ($2.81).
Verastem Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $7.00 | $10.00 |
| Last Closing Price | $2.81 | $2.81 | $2.81 |
| Upside/Downside | -100.00% | 149.11% | 255.87% |
In the current month, the average price target of Verastem stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Verastem's last price of $2.81. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 28, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jun 15, 2023 | Mizuho Securities | Positive | Buy | Upgrade |
| Jun 15, 2023 | Citigroup | - | Buy | Upgrade |
| Jun 15, 2023 | Mizuho Securities | - | Positive | Upgrade |
| Apr 26, 2022 | Zacks Investment Research | - | Hold | Upgrade |
| Apr 14, 2022 | RBC Capital | - | Outperform | Initialise |
Verastem's last stock rating was published by RBC Capital on May 28, 2024. The company gave VSTM a "Outperform" rating, the same as its previous rate.
Verastem Financial Forecast
Verastem Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jul 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.60M | $2.00K | $500.00K | $1.01M | $506.00K | $78.65M | $4.31M | $5.06M | $3.62M | $9.03M | $3.14M | $1.67M | $15.51M | $10.00M |
| Avg Forecast | $2.47M | $567.33K | $650.00K | $200.00K | $133.33K | $66.67K | $66.67K | - | $7.12M | $33.33K | $16.67K | $16.67K | $1.71K | $46.75K | $1.50M | $37.50K | $50.00K | $1.01M | $3.19M | $26.60M | $4.04M | $3.96M | $4.49M | $7.72M | $2.33M | $2.52M | $22.46M | $11.33M |
| High Forecast | $2.47M | $567.33K | $650.00K | $200.00K | $133.33K | $66.67K | $66.67K | - | $7.12M | $33.33K | $16.67K | $16.67K | $2.06K | $56.10K | $1.50M | $37.50K | $50.00K | $1.21M | $3.19M | $26.60M | $4.04M | $3.96M | $4.49M | $7.72M | $2.33M | $2.52M | $26.95M | $13.60M |
| Low Forecast | $2.47M | $567.33K | $650.00K | $200.00K | $133.33K | $66.67K | $66.67K | - | $7.12M | $33.33K | $16.67K | $16.67K | $1.37K | $37.40K | $1.50M | $37.50K | $50.00K | $804.80K | $3.19M | $26.60M | $4.04M | $3.96M | $4.49M | $7.72M | $2.33M | $2.52M | $17.97M | $9.07M |
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 2 | 4 | 2 | 2 | 8 | 17 | 20 | 9 | 8 | 8 | 16 | 14 | 8 | 8 | 10 | 13 | 5 | 5 | 5 | 12 | 16 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.73% | 0.05% | 10.00% | 1.00% | 0.16% | 2.96% | 1.07% | 1.28% | 0.80% | 1.17% | 1.35% | 0.66% | 0.69% | 0.88% |
Verastem's average Quarter revenue forecast for Jul 22 based on 20 analysts is $46.75K, with a low forecast of $37.40K, and a high forecast of $56.10K. VSTM's average Quarter revenue forecast represents a -98.20% decrease compared to the company's last Quarter revenue of $2.60M (Mar 22).
Verastem EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jul 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 2 | 4 | 2 | 2 | 8 | 17 | 20 | 9 | 8 | 8 | 16 | 14 | 8 | 8 | 10 | 13 | 5 | 5 | 5 | 12 | 16 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-18.88M | $-20.29M | $-14.95M | $-17.37M | - | $-16.91M | $-14.81M | $-15.86M | $-14.01M | $-19.38M | $15.28M | $-20.68M | $-26.81M | $-32.81M | $-24.56M | $-36.45M | $-32.61M | $-20.68M | $-17.18M |
| Avg Forecast | $-1.25M | $-287.94K | $-329.89K | $-101.50K | $-67.67K | $-33.84K | $-33.84K | - | $-3.61M | $-16.92K | $-8.46K | $-8.46K | $-8.46M | $-13.18M | $-14.77K | $-9.05M | $-14.10M | $-14.01M | $-1.62M | $16.80M | $-22.06M | $-12.07M | $-2.28M | $-27.23M | $-31.34M | $-28.36M | $-27.07M | $-19.21M |
| High Forecast | $-1.25M | $-287.94K | $-329.89K | $-101.50K | $-67.67K | $-33.84K | $-33.84K | - | $-3.61M | $-16.92K | $-8.46K | $-8.46K | $-6.77M | $-10.55M | $-11.81K | $-7.24M | $-11.28M | $-11.21M | $-1.62M | $20.16M | $-17.65M | $-9.65M | $-2.28M | $-21.78M | $-25.08M | $-22.69M | $-21.66M | $-15.36M |
| Low Forecast | $-1.25M | $-287.94K | $-329.89K | $-101.50K | $-67.67K | $-33.84K | $-33.84K | - | $-3.61M | $-16.92K | $-8.46K | $-8.46K | $-10.16M | $-15.82M | $-17.72K | $-10.86M | $-16.92M | $-16.81M | $-1.62M | $13.44M | $-26.47M | $-14.48M | $-2.28M | $-32.67M | $-37.61M | $-34.03M | $-32.49M | $-23.05M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1115.74% | 2399.15% | 1766.97% | 2.05% | - | 1144.93% | 1.64% | 1.13% | 1.00% | 11.96% | 0.91% | 0.94% | 2.22% | 14.39% | 0.90% | 1.16% | 1.15% | 0.76% | 0.89% |
14 analysts predict VSTM's average Quarter EBITDA for Dec 20 to be $-1.62M, with a high of $-1.62M and a low of $-1.62M. This is -110.61% lower than Verastem's previous annual EBITDA (Sep 20) of $15.28M.
Verastem Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jul 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 2 | 4 | 2 | 2 | 8 | 17 | 20 | 9 | 8 | 8 | 16 | 14 | 8 | 8 | 10 | 13 | 5 | 5 | 5 | 12 | 16 |
| Net Income | - | - | - | - | - | - | - | - | - | $-20.00M | $-24.28M | $-12.85M | $-18.10M | - | $-16.97M | $-22.79M | $-16.90M | $-15.03M | $-19.86M | $13.14M | $-23.01M | $-37.99M | $-38.77M | $-30.14M | $-42.19M | $-38.10M | $-21.67M | $-18.37M |
| Avg Forecast | $-16.39M | $-16.52M | $-17.73M | $-18.53M | $-18.00M | $-18.76M | $-25.85M | $-27.68M | $-16.42M | $-22.64M | $-28.02M | $-26.86M | $-13.02M | $-14.05M | $-14.84K | $-13.92M | $-15.02M | $-15.03M | $-27.34M | $14.45M | $-24.54M | $-17.10M | $-146.37M | $-33.41M | $-36.29M | $-33.13M | $-28.37M | $-20.53M |
| High Forecast | $-16.39M | $-16.52M | $-17.73M | $-18.53M | $-18.00M | $-17.18M | $-25.85M | $-27.68M | $-15.82M | $-22.64M | $-28.02M | $-26.86M | $-10.42M | $-11.24M | $-11.87K | $-11.14M | $-12.02M | $-12.02M | $-27.34M | $17.34M | $-19.64M | $-13.68M | $-146.37M | $-26.73M | $-29.03M | $-26.51M | $-22.70M | $-16.42M |
| Low Forecast | $-16.39M | $-16.52M | $-17.73M | $-18.53M | $-18.00M | $-21.41M | $-25.85M | $-27.68M | $-16.82M | $-22.64M | $-28.02M | $-26.86M | $-15.62M | $-16.86M | $-17.81K | $-16.71M | $-18.03M | $-18.04M | $-27.34M | $11.56M | $-29.45M | $-20.51M | $-146.37M | $-40.10M | $-43.54M | $-39.76M | $-34.05M | $-24.63M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.88% | 0.87% | 0.48% | 1.39% | - | 1143.39% | 1.64% | 1.13% | 1.00% | 0.73% | 0.91% | 0.94% | 2.22% | 0.26% | 0.90% | 1.16% | 1.15% | 0.76% | 0.89% |
Verastem's average Quarter net income forecast for Dec 20 is $-27.34M, with a range of $-27.34M to $-27.34M. VSTM's average Quarter net income forecast represents a -308.13% decrease compared to the company's last Quarter net income of $13.14M (Sep 20).
Verastem SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jul 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 2 | 4 | 2 | 2 | 8 | 17 | 20 | 9 | 8 | 8 | 16 | 14 | 8 | 8 | 10 | 13 | 5 | 5 | 5 | 12 | 16 |
| SG&A | - | - | - | - | - | - | - | - | - | $7.36M | $7.40M | $7.33M | $6.42M | - | $5.93M | $5.52M | $6.71M | $6.22M | $40.84M | $20.61M | $15.44M | $19.60M | $23.73M | $22.15M | $29.30M | $26.43M | $25.46M | $15.81M |
| Avg Forecast | $14.26M | $3.28M | $3.75M | $1.15M | $769.97K | $384.99K | $384.99K | - | $41.12M | $192.49K | $96.25K | $96.25K | $9.89K | $269.97K | $5.19K | $216.55K | $288.74K | $5.81M | $18.43M | $22.68M | $23.34M | $22.85M | $25.95M | $44.58M | $13.44M | $14.54M | $129.70M | $65.45M |
| High Forecast | $14.26M | $3.28M | $3.75M | $1.15M | $769.97K | $384.99K | $384.99K | - | $41.12M | $192.49K | $96.25K | $96.25K | $11.87K | $323.96K | $6.23K | $216.55K | $288.74K | $6.97M | $18.43M | $27.21M | $23.34M | $22.85M | $25.95M | $44.58M | $13.44M | $14.54M | $155.64M | $78.54M |
| Low Forecast | $14.26M | $3.28M | $3.75M | $1.15M | $769.97K | $384.99K | $384.99K | - | $41.12M | $192.49K | $96.25K | $96.25K | $7.91K | $215.98K | $4.15K | $216.55K | $288.74K | $4.65M | $18.43M | $18.14M | $23.34M | $22.85M | $25.95M | $44.58M | $13.44M | $14.54M | $103.76M | $52.36M |
| Surprise % | - | - | - | - | - | - | - | - | - | 38.25% | 76.87% | 76.15% | 649.11% | - | 1143.13% | 25.50% | 23.25% | 1.07% | 2.22% | 0.91% | 0.66% | 0.86% | 0.91% | 0.50% | 2.18% | 1.82% | 0.20% | 0.24% |
Verastem's average Quarter SG&A projection for Dec 23 is $41.12M, based on 4 Wall Street analysts, with a range of $41.12M to $41.12M. The forecast indicates a 458.42% rise compared to VSTM last annual SG&A of $7.36M (Sep 23).
Verastem EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jul 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 2 | 4 | 2 | 2 | 8 | 17 | 20 | 9 | 8 | 8 | 16 | 14 | 8 | 8 | 10 | 13 | 5 | 5 | 5 | 12 | 16 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.75 | $-1.37 | $-0.06 | $-0.09 | - | $-0.09 | $-0.13 | $-0.10 | $-0.09 | $-0.12 | $0.08 | $-0.14 | $-0.35 | $-0.36 | $-0.41 | $-0.57 | $-0.52 | $-0.29 | $-0.30 |
| Avg Forecast | $-0.61 | $-0.61 | $-0.66 | $-0.69 | $-0.67 | $-0.70 | $-0.96 | $-1.03 | $-0.61 | $-0.84 | $-1.04 | $-1.00 | $-1.46 | $-1.32 | $-0.98 | $-1.01 | $-1.00 | $-1.08 | $-1.02 | $0.52 | $-1.76 | $-2.67 | $-5.46 | $-5.49 | $-6.02 | $-5.48 | $-0.55 | $-0.38 |
| High Forecast | $-0.61 | $-0.61 | $-0.66 | $-0.69 | $-0.67 | $-0.64 | $-0.96 | $-1.03 | $-0.59 | $-0.84 | $-1.04 | $-1.00 | $-1.46 | $-1.32 | $-0.98 | $-1.01 | $-1.00 | $-1.08 | $-1.02 | $0.52 | $-1.76 | $-2.67 | $-5.46 | $-5.49 | $-6.02 | $-5.48 | $-0.44 | $-0.30 |
| Low Forecast | $-0.61 | $-0.61 | $-0.66 | $-0.69 | $-0.67 | $-0.80 | $-0.96 | $-1.03 | $-0.63 | $-0.84 | $-1.04 | $-1.00 | $-1.46 | $-1.32 | $-0.98 | $-1.01 | $-1.00 | $-1.08 | $-1.02 | $0.52 | $-1.76 | $-2.67 | $-5.46 | $-5.49 | $-6.02 | $-5.48 | $-0.66 | $-0.46 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.89% | 1.31% | 0.06% | 0.06% | - | 0.09% | 0.13% | 0.10% | 0.08% | 0.11% | 0.15% | 0.08% | 0.13% | 0.07% | 0.07% | 0.09% | 0.09% | 0.53% | 0.79% |
According to 14 Wall Street analysts, Verastem's projected average Quarter EPS for Dec 20 is $-1.02, with a low estimate of $-1.02 and a high estimate of $-1.02. This represents a -1375.00% decrease compared to VSTM previous annual EPS of $0.08 (Sep 20).
Verastem Peer Comparison by Price Target
VSTM Forecast FAQ
Is Verastem a good buy?
Yes, according to 4 Wall Street analysts, Verastem (VSTM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of VSTM's total ratings.
What is VSTM's price target?
Verastem (VSTM) average price target is $8.33 with a range of $5 to $13, implying a 196.44% from its last price of $2.81. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Verastem stock go up soon?
According to Wall Street analysts' prediction for VSTM stock, the company can go up by 196.44% (from the last price of $2.81 to the average price target of $8.33), up by 362.63% based on the highest stock price target, and up by 77.94% based on the lowest stock price target.
Can Verastem stock reach $4?
VSTM's average twelve months analyst stock price target of $8.33 supports the claim that Verastem can reach $4 in the near future.
What are Verastem's analysts' financial forecasts?
Verastem's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $266.67K (high $266.67K, low $266.67K), average EBITDA is $-135K (high $-135K, low $-135K), average net income is $-90.29M (high $-88.705M, low $-92.933M), average SG&A $1.54M (high $1.54M, low $1.54M), and average EPS is $-3.362 (high $-3.303, low $-3.461). VSTM's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.89M (high $3.89M, low $3.89M), average EBITDA is $-1.972M (high $-1.972M, low $-1.972M), average net income is $-69.167M (high $-69.167M, low $-69.167M), average SG&A $22.44M (high $22.44M, low $22.44M), and average EPS is $-2.575 (high $-2.575, low $-2.575).
Did the VSTM's actual financial results beat the analysts' financial forecasts?
Based on Verastem's last annual report (Dec 2020), the company's revenue was $88.52M, beating the average analysts forecast of $37.79M by 134.23%. Apple's EBITDA was $-47.59M, beating the average prediction of $-18.941M by 151.25%. The company's net income was $-67.726M, beating the average estimation of $-54.532M by 24.20%. Apple's SG&A was $62.76M, missing the average forecast of $87.3M by -28.11%. Lastly, the company's EPS was $-5.3, beating the average prediction of $-4.93 by 7.51%. In terms of the last quarterly report (Mar 2022), Verastem's revenue was $2.6M, beating the average analysts' forecast of $1.5M by 73.07%. The company's EBITDA was $-16.906M, beating the average prediction of $-14.766K by 114392.75%. Verastem's net income was $-16.969M, beating the average estimation of $-14.841K by 114238.66%. The company's SG&A was $5.93M, beating the average forecast of $5.19K by 114213.23%. Lastly, the company's EPS was $-0.0911, missing the average prediction of $-0.984 by -90.74%